US FDA plans ultra-fast review of 3 psychedelic drugs after Trump directive
Culture Index
Score Breakdown
Relevance
3/25
Freshness
24/25
Authority
18/20
Brand Signal
11/15
Depth
7/15
5-Axis Cultural Radar
The Food and Drug Administration said on Friday it will offer ultra-fast review to three psychedelic drugs being developed to treat mental health conditions, including depression, the latest indication of the Trump administration’s commitment to the experimental treatment approach. President Donald Trump signed an executive order last weekend directing the FDA and other federal agencies to speed a
